BioSpace News Archive

RxSight, Inc., an ophthalmic medical device company, announced that it will report financial results for the third quarter of 2021 after the market close on Wednesday, November 10, 2021.

Align Technology, Inc. announced the findings of a multi-center clinical study, “Reflected near-infrared light versus bite-wing radiography for the detection of proximal caries: a multicenter prospective clinical study conducted in private practices,” published in the peer-reviewed Journal of Dentistry.

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), today announced that the Company will report third quarter 2021 financial results on Wednesday, November 10, 2021.

Repare Therapeutics Inc. today announced the commencement of a proposed underwritten public offering of $75.0 million of its common shares.

TYME Technologies, Inc. today announced that the Company will report its second quarter 2022 financial results on Monday, November 8, 2021 at 8:30 AM ET.

TherapeuticsMD, Inc. today announced that it will report its third quarter 2021 financial results on Thursday, November 11, 2021, before the opening of the U.S. financial markets.

Genomma Lab Internacional, S.A.B. de C.V . (BMV: LAB B) (“Genomma Lab” or “the Company”), today announced its results for the third quarter ended September 30, 2021

HUTCHMED Limited announces that it has initiated a Phase III trial in China of HMPL-523, a novel, investigational spleen tyrosine kinase inhibitor, in adult patients with primary immune thrombocytopenia, an autoimmune disorder that can lead to increased risk of bleeding.

Repare Therapeutics Inc., a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, announced the pricing of an upsized underwritten public offering of 4,000,000 of its common shares at a public offering price of $22.00 per share, for total gross proceeds of $88.0 million, before deducting underwriting commissions and offering expenses payable by Repare.

Eurofins Eaton Analytical is prepared for UCMR5 testing in advance of anticipated rule release.